INT21953

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 1990
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 12
Total Number 13
Disease Relevance 4.72
Pain Relevance 4.56

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

aging (Ednra) plasma membrane (Ednra) signal transducer activity (Ednra)
Anatomy Link Frequency
coronary artery 2
iris 2
smooth muscle 1
brain 1
Ednra (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 150 100.00 Very High Very High Very High
agonist 74 100.00 Very High Very High Very High
Opioid 3 100.00 Very High Very High Very High
Eae 28 99.84 Very High Very High Very High
Neurotransmitter 16 99.76 Very High Very High Very High
tetrodotoxin 4 98.76 Very High Very High Very High
Morphine 3 95.80 Very High Very High Very High
analgesia 1 95.32 Very High Very High Very High
antinociception 1 94.08 High High
Ventral tegmentum 2 93.84 High High
Disease Link Frequency Relevance Heat
Heart Rate Under Development 4 98.88 Very High Very High Very High
Pressure And Volume Under Development 36 97.84 Very High Very High Very High
Increased Venous Pressure Under Development 67 97.28 Very High Very High Very High
Congenital Anomalies 24 96.40 Very High Very High Very High
Coronary Artery Disease 4 95.60 Very High Very High Very High
Stress 30 95.52 Very High Very High Very High
Hyperlipidemia 22 95.04 Very High Very High Very High
Renal Failure 2 94.56 High High
Diabetes Mellitus 58 94.40 High High
Cerebrovascular Disease 2 93.96 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In conclusion, ET interacts with two different receptor types, ETA and non-ETA receptors (probably ETB) which exist post- and presynaptically at cholinergic neuroeffector junctions of the rat iris preparation.
ETA Binding (interacts) of in iris
1) Confidence 0.33 Published 1994 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 7935856 Disease Relevance 0 Pain Relevance 0.27
In conclusion, ET interacts with two different receptor types, ETA and non-ETA receptors (probably ETB) which exist post- and presynaptically at cholinergic neuroeffector junctions of the rat iris preparation.
ETA Binding (interacts) of in iris
2) Confidence 0.22 Published 1994 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 7935856 Disease Relevance 0 Pain Relevance 0.27
ETA appears to be at the center in modulating the vascular activity, and an upregulated ETA has been found under multiple conditions: congestive heart failure, hypertension, atherosclerosis, endothelial dysfunction, coronary artery diseases, renal failure, cerebrovascular disease, pulmonary arterial hypertension, and sepsis.3 Interestingly, some substances and prescriptions in Traditional Chinese Medicine (TCM) may be effective in reversing endothelial insults by suppressing the activated ETA, such as quercetin, isorhamnetin, or chelerythrine (protein kinase C (PKC) inhibitor), a modified rehmannia decoction (Liu-wei-di-huang decoction), and total triterpene acids isolated from corni fructus.1,4,5
ETA Binding (found) of in coronary artery associated with pressure and volume under development, heart rate under development, coronary artery disease, renal failure, increased venous pressure under development, sepsis, cerebrovascular disease, kinase c and pulmonary hypertension
3) Confidence 0.18 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941789 Disease Relevance 1.88 Pain Relevance 0.11
ETA appears to be at the center in modulating the vascular activity, and an upregulated ETA has been found under multiple conditions: congestive heart failure, hypertension, atherosclerosis, endothelial dysfunction, coronary artery diseases, renal failure, cerebrovascular disease, pulmonary arterial hypertension, and sepsis.3 Interestingly, some substances and prescriptions in Traditional Chinese Medicine (TCM) may be effective in reversing endothelial insults by suppressing the activated ETA, such as quercetin, isorhamnetin, or chelerythrine (protein kinase C (PKC) inhibitor), a modified rehmannia decoction (Liu-wei-di-huang decoction), and total triterpene acids isolated from corni fructus.1,4,5
ETA Binding (be) of in coronary artery associated with pressure and volume under development, heart rate under development, coronary artery disease, renal failure, increased venous pressure under development, sepsis, cerebrovascular disease, kinase c and pulmonary hypertension
4) Confidence 0.18 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941789 Disease Relevance 1.90 Pain Relevance 0.11
These studies suggest that the central ET and opioid systems functionally interact.
ET Binding (interact) of associated with opioid
5) Confidence 0.16 Published 2004 Journal Neuroscience Section Abstract Doc Link 15541896 Disease Relevance 0 Pain Relevance 0.82
Binding of Rh-ET-1 (16 nM) to smooth muscle (Fig. 6D) was reduced by BQ788 (1 µM; Fig. 6E) and was prevented by presence of either ET-1 (16 nM) or of both BQ788 (1 µM) and BQ123 (1 µM)[2] indicating selective binding to ETA- and ETB-receptors.
ETA Binding (binding) of in smooth muscle
6) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2879375 Disease Relevance 0 Pain Relevance 0.43
Several classes of low molecular weight ETA-selective or mixed ET-receptor antagonists have been developed primarily on the basis of prevention of the binding of ET-1 to its receptors[4], [5], [6], [19], [20], [21].
ET-receptor Binding (binding) of associated with antagonist
7) Confidence 0.12 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2879375 Disease Relevance 0.36 Pain Relevance 0.25
Modulation of ET-1/ETA-receptor binding
ETA-receptor Binding (binding) of
8) Confidence 0.12 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2879375 Disease Relevance 0 Pain Relevance 0.40
Although the maximal pressor responses of the two peptides were comparable the renal resistance did not change with Big-ET but increased 4-fold with ET-1.
Big-ET Neg (not) Binding (change) of
9) Confidence 0.10 Published 1990 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2226627 Disease Relevance 0.09 Pain Relevance 0
On the other hand, the interaction between bilateral infusion of mu-receptor agonist Tyr-D-Ala-Gly-NMe-Phe-Gly-ol (DAGO) and EtOH on locomotor activity is complex.
EtOH Binding (interaction) of associated with eae and agonist
10) Confidence 0.06 Published 1995 Journal Alcohol. Clin. Exp. Res. Section Abstract Doc Link 7573807 Disease Relevance 0 Pain Relevance 0.74
Results from this study support our hypothesis that a low dose of EtOH that does not modify behavior can interact with neurotransmitter systems in the brain and modify drug-induced locomotor activity.
EtOH Binding (interact) of in brain associated with neurotransmitter and eae
11) Confidence 0.05 Published 1995 Journal Alcohol. Clin. Exp. Res. Section Abstract Doc Link 7573807 Disease Relevance 0 Pain Relevance 0.75
BQ-123 was shown to antagonize the S6c pressor response partially, suggesting a possible interaction between the ET(A) and ET(B) receptors in the ferret.
ET Binding (interaction) of
12) Confidence 0.01 Published 1999 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 10470993 Disease Relevance 0.17 Pain Relevance 0.19
BQ-123 was shown to antagonize the S6c pressor response partially, suggesting a possible interaction between the ET(A) and ET(B) receptors in the ferret.
ET Binding (interaction) of
13) Confidence 0.01 Published 1999 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 10470993 Disease Relevance 0.17 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox